For a patient with PSMA+ mCRPC but relatively low SUV values, does that influence your decision to use 177Lu-PSMA or discussion with patient regarding potential benefit?
Would you use an FDG PET to further inform decision?
Answer from: Medical Oncologist at Community Practice
In general, the use of PSMA-lutetium is primarily utilized in patients with advanced metastatic castration resistant prostate cancer which has been heavily pre-treated with at least one novel anti-androgen (and often several) and one or two taxane based therapies.
No prospective trial has addressed...
Sign in or Register to read more